Abreva

(Docosanol 10%)

Phase 2Small molecule

HHALEON

Abreva is one of 10 small molecule programs targeting Herpes Labialis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Herpes LabialisActive, not recruiting

Herpes LabialisPhase 2

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Herpes Labialis

#DrugCompanyPhaseTrials

Famvir

Novartis

Approved

2 2

Valtrex

GGlaxo Dba Glaxosmithkline

Zovirax

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Glutamine

1 6

NB-001

NNobias Therapeutics, Inc.

Phase 3

3 7

Abreva

HHALEON

Phase 2

2 8

Squaric Acid Dibutyl Ester

SSquarex, LLC

Phase 2

1 9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 10

ME-609

MMedivir

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Herpes Labialis2 trials

Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)

Unknown status·HHadassah Medical Organization·Phase 4·NCT00467662·75 enrolled

An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis

Unknown status·LLaboratoire Boreaderme Inc.·Phase 2·NCT03977792·164 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 25, 2000

ABREVA

NDA NDA020941

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Docosanol 10%. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docosanol 10% compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docosanol 10%. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020941). U.S. Food & Drug Administration.
[5]
SEC EDGAR — HALEON company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHALEON

Abreva

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Herpes Labialis2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News